Project Grant R21AI184169
Award Date
1/6/25
Completion Date
12/31/26
Dollars Obligated
$244K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This $815,573 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to investigate the mechanisms driving persistent inflammation in perinatally HIV-infected adolescents maintained on long-term antiretroviral therapy (ART). The goal is to identify the HIV-induced inflammatory networks and viral factors responsible for this chronic inflammation, which can lead to metabolic, neurocognitive,...
This federal Project Grant award of $685,637 from the National Institute of Child Health and Human Development (NICHD) under CFDA 93.865 - Child Health and Human Development Extramural Research aims to enhance research on inflammation and cognitive health among adolescents and young adults (AYA) living with perinatally acquired HIV (PHIV) and adversity in Uganda. The award supports a comprehensive study to investigate the relationship between immune dysfunction, inflammation, and...
This federal Project Grant award, funded by the National Institutes of Health (NIH) under the Child Health and Human Development Extramural Research program (CFDA 93.865), supports a comprehensive longitudinal study to assess the long-term immunologic, cardiovascular, metabolic, and neurocognitive outcomes in individuals with perinatal HIV exposure in Kenya. The $756,077 award, effective August 2024 through April 2029, aims to determine whether viral suppression on prolonged antiretroviral...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $3,356,188 to characterize HIV-1 proviral reservoirs in neonates and infants receiving very early antiretroviral therapy (ART) and combination ART with broadly neutralizing antibodies. The goal is to investigate strategies for achieving ART-free remission in infants through understanding the proviral pool...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $647,800.00 to characterize how the antiviral activity of antiretroviral therapy (ART) and broadly neutralizing antibodies (bNAbs) wane during treatment interruption studies for people with HIV. The award will leverage existing data and technologies to quantify ART levels in plasma, cells, and tissue to understand...
This Project Grant award of $448,765 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to characterize the persistence and functionality of HIV-specific CD8+ T cell responses in children who received early antiretroviral therapy (ART) for perinatal HIV infection. The study aims to: (1) determine the magnitude, phenotype, and functionality of HIV-specific CD8+ T cells that persist in...
This federal Project Grant award of $1,314,701.00, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to address research gaps in optimizing dolutegravir-based antiretroviral therapy (ART) for children and adolescents. The primary awardee, the University of Florida, will lead research studies to better understand dolutegravir pharmacokinetics, safety, and efficacy in pediatric and adolescent...
This federal Project Grant award of $793,247 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to improve the health of people living with HIV. The key objectives are to: Develop and implement a data-driven algorithm to assign validated causes of hospitalizations among people with HIV, and estimate trends and patterns in cause-specific hospitalization rates. Develop hospitalization...
This federal Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 Child Health and Human Development Extramural Research) provides $534,721 to Oregon Health & Science University to study the impact of antiretroviral therapy (ART) on fetal immune system development in a rhesus macaque model of simian immunodeficiency virus (SIV) infection. The research aims to determine the effects of maternal SIV infection and ART on the development and...
This $431,712 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to improve HIV testing among children under five in rural Uganda. The 2-year grant, awarded to the Regents of the University of California, San Francisco, will fund an innovative approach to increase pediatric HIV testing by adapting a successful traditional healer-facilitated HIV testing program for children 18 months to 5 years...